Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis…
73% of enterprises have launched AI, including generative AI, across marketing with 52% of deployments achieving business value: Infosys CMO Radar
AI-fluent CMOs are becoming a transformative force in business; 62% see their…
